IDEAYA Biosciences Past Earnings Performance

Past criteria checks 0/6

IDEAYA Biosciences's earnings have been declining at an average annual rate of -33.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.1% per year.

Key information

-33.1%

Earnings growth rate

10.7%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate18.1%
Return on equity-15.1%
Net Margin-4,541.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How IDEAYA Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:30J Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244-178350
30 Jun 2412-154340
31 Mar 2416-129300
31 Dec 2323-113280
30 Sep 2323-103270
30 Jun 2345-74260
31 Mar 2347-68240
31 Dec 2251-59240
30 Sep 2250-53230
30 Jun 2229-66220
31 Mar 2232-55210
31 Dec 2128-50200
30 Sep 2136-37190
30 Jun 2136-30170
31 Mar 2127-31170
31 Dec 2020-34150
30 Sep 209-40140
30 Jun 200-4613-17
31 Mar 200-4411-8
31 Dec 190-42100
30 Sep 190-4098
30 Jun 190-42737
31 Mar 190-38635
31 Dec 180-3450

Quality Earnings: 30J is currently unprofitable.

Growing Profit Margin: 30J is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 30J is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.

Accelerating Growth: Unable to compare 30J's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 30J is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 30J has a negative Return on Equity (-15.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 03:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IDEAYA Biosciences, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Zhiqiang ShuBerenberg
Justin ZelinBTIG